Skip to main content
Clinical Trials/NCT01291836
NCT01291836CompletedNot Applicable

Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin (N-GAL) Evaluation of Symptomatic Heart Failure Study (AKINESIS)

Alere San Diego13 sites in 7 countries930 target enrollmentStarted: December 2010Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
930
Locations
13
Primary Endpoint
Evaluating the Efficacy of the Triage NGAL Test as an Aid to Diagnosis of Acute Kidney Injury (AKI) in Patients Admitted to the Hospital With Symptoms of Acute Heart Failure.

Study Overview

Brief Summary

AKINESIS is a clinical study to assess the utility of blood and urine NGAL tests in predicting worsening kidney function in patients who present with acute heart failure (AHF) and who are treated with diuretics. It is believed that rising NGAL levels in the blood and/or urine can predict acute kidney injury. It is also believed that patients who are admitted to the hospital with high NGAL levels in the blood/urine will have poorer outcomes.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Subjects must be at least 18 years of age.
  • Subjects must present to the hospital with one or more signs or symptoms of acute heart failure (AHF). Signs and symptoms include shortness of breath from walking, rales or crackles, galloping heart rhythm, jugular venous distension, trouble breathing at rest or when lying down, waking breathless at night, using more than 2 pillows to sleep, tiring easily, swelling of feet, ankles or legs, frequent coughing, a cough that produces mucous or blood-tinged sputum, or a dry cough when lying flat.
  • Subjects must receive IV diuretics, or there must be an intent to treat with IV diuretics.
  • Subjects must be willing and able to comply with all aspects of the protocol.
  • Subjects must provide signed informed consent.

Exclusion Criteria

  • Subjects that present with symptoms consistent with acute coronary syndromes (AMI or UA) as the chief cause of the current episode of AHF.
  • Subjects already on dialysis prior to enrollment or if dialysis initiation is already planned during the current hospital visit.
  • Subjects that have had any major organ transplant (heart, lung, kidney, or liver).
  • Subjects that have participated in a drug treatment study within the past 30 days or if they have already been enrolled as a subject in this study.
  • Women who verbally report being pregnant at the time of screening and anyone belonging to a vulnerable population that is deemed inappropriate for inclusion into the study by the IRB/EC.

Outcomes

Primary Outcomes

Evaluating the Efficacy of the Triage NGAL Test as an Aid to Diagnosis of Acute Kidney Injury (AKI) in Patients Admitted to the Hospital With Symptoms of Acute Heart Failure.

Time Frame: First week of hospitalization.

Efficacy determined by the evaluation of the area under the Receiver Operator Curve (ROC) generated from the study primary endpoint data. The units on both axes of the ROC curve are dimensionless proportions from 0 to 1.

Evaluating the Efficacy of the Triage NGAL Test as an Aid in Predicting Poorer Outcomes in Patients Admitted to the Hospital With Admitted With Symptoms of Acute Heart Failure.

Time Frame: ~30 days

Efficacy determined by the evaluation of the area under the Receiver Operator Curve (ROC) generated from the study primary endpoint data. The units on both axes of the ROC curve are dimensionless proportions from 0 to 1.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Alere San Diego
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (13)

Loading locations...

Similar Trials